PDSB
Income statement / Annual
Last year (2023), PDS Biotechnology Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, PDS Biotechnology Corporation's net income was -$42.94 M.
See PDS Biotechnology Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$57,326.00 |
$49,078.00 |
$246,388.00 |
$176,292.00 |
$98,414.00 |
$69,118.00 |
$182,918.00 |
$100,117.00 |
$53,116.00 |
$0.00 |
| Gross Profit |
-$57,326.00 |
-$49,078.00 |
-$246,388.00 |
-$176,292.00 |
-$98,414.00 |
-$69,118.00 |
-$182,918.00 |
-$100,117.00 |
-$53,116.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$27.76 M
|
$29.43 M
|
$11.25 M
|
$7.92 M
|
$6.10 M
|
$16.07 M
|
$34.31 M
|
$24.83 M
|
$17.84 M
|
$8.47 M
|
| General & Administrative
Expenses |
$15.02 M
|
$12.24 M
|
$10.18 M
|
$6.96 M
|
$10.98 M
|
$14.29 M
|
$17.65 M
|
$14.69 M
|
$8.66 M
|
$4.72 M
|
| Selling & Marketing
Expenses |
$264,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$15.28 M
|
$12.24 M
|
$10.18 M
|
$6.96 M
|
$10.98 M
|
$14.29 M
|
$17.65 M
|
$14.69 M
|
$8.66 M
|
$4.72 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$15,608.00 |
$3.95 B |
$12.74 B |
$0.00 |
-$163,463.00 |
-$1.88 M |
$0.00 |
| Operating Expenses |
$43.05 M |
$41.67 M |
$21.44 M |
$14.90 M |
$17.08 M |
$30.36 M |
$51.97 M |
$39.51 M |
$26.50 M |
$13.19 M |
| Cost And Expenses |
$43.05 M |
$41.67 M |
$21.44 M |
$14.90 M |
$17.08 M |
$30.36 M |
$51.97 M |
$39.51 M |
$26.50 M |
$13.19 M |
| Interest Income |
$2.90 M |
$935,180.00 |
$4,346.00 |
$55,006.00 |
$353,490.00 |
$871,879.00 |
$700,903.00 |
$212,299.00 |
$9,084.00 |
$2,941.00 |
| Interest Expense |
$4.21 M |
$1.32 M |
$0.00 |
$0.00 |
$33,559.00 |
$1.43 M |
$2.18 M |
$1.20 M |
$816,494.00 |
$183,179.00 |
| Depreciation &
Amortization |
$57,326.00
|
$49,078.00
|
$246,388.00
|
$176,292.00
|
$98,414.00
|
$69,118.00
|
$182,918.00
|
$100,117.00
|
$53,116.00
|
$31,229.00
|
| EBITDA |
-$42.99 M
|
-$40.74 M
|
-$21.43 M
|
-$14.83 M
|
-$16.73 M
|
-$29.31 M
|
-$51.27 M
|
-$39.46 M
|
-$28.37 M
|
-$13.16 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.30 M
|
-$381,339.00
|
$4,346.00
|
$55,006.00
|
$13.65 M
|
-$12.74 M
|
-$1.48 M
|
-$163,463.00
|
-$1.88 M
|
$582,360.00
|
| Income Before Tax |
-$44.35 M |
-$42.05 M |
-$21.43 M |
-$14.85 M |
-$7.38 M |
-$43.65 M |
-$53.45 M |
-$40.67 M |
-$29.19 M |
-$12.79 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.41 M |
-$1.20 M |
-$4.52 M |
-$135,683.00 |
-$381,513.00 |
-$2.78 M |
-$2.59 M |
-$1.85 M |
-$1.11 M |
-$590,675.00 |
| Net Income |
-$42.94 M |
-$40.85 M |
-$16.92 M |
-$14.85 M |
-$7.00 M |
-$40.87 M |
-$50.86 M |
-$38.82 M |
-$28.08 M |
-$12.20 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-26.16 |
-33.47 |
-26.9 |
-69.43 |
-16.15 |
| EPS Diluted |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-26.16 |
-33.47 |
-26.9 |
-69.43 |
-16.15 |
| Weighted Average Shares
Out |
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$1.56 M
|
$1.52 M
|
$1.44 M
|
$404,396.00
|
$755,357.00
|
| Weighted Average Shares
Out Diluted |
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$1.56 M
|
$1.52 M
|
$1.44 M
|
$404,396.00
|
$755,357.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
